Vast Potential for Clinical Trial Opportunities; Adipose Tissue Derived Mesenchymal Stem Cells

ABSTRACT

Introduction: This is a research innovation that aims to provide an additional therapeutic tool. It will open up a vast panorama of regenerative medicine by application of Adipose Derived Mesenchymal Stem Cells (ADMSCs). ADMSCs are selected since a large amount is available for lipoaspiration and a larger percentage (30%) of Mesenchymal Stem Cells (MSCs) obtainable there from. The applications in clinical practice extend across Mesoderm, Endoderm and Ectoderm layers1. Material and Methods: There are three products that can be derived from the lipoaspirate. They are (1) Stromal Vascular Fraction (SVF), (2) Islet Cell Aggregates (ICAs) Translated from ADMSCs, (3) and ADMSCs with ~95% purity. They are deployed to illustrate the safety and efficacy in clinical trials for (1) Mesoderm Translation as in Osteoarthritis Knee, (2) Endoderm translation to Insulin-producing Cells as applicable to diabetes, and (3) Ectodermal Translation as applicable on Non-healing Indolent Ulcers on the Skin. Results: All three products are found safe with no adverse side effects. Proof of concept studies along with initial clinical trials for Osteoarthritis, Diabetes Types I and II, and Non-healing ulcer of any aetiology is demonstrated with objective evidence. Discussion: The evidence based on the results of the clinical trials across all three Germinal Layers is cited along with literature support. Results are explained based on a plausible scientific hypothesis. Conclusion: The study enunciates that Autologous SVF and ADMSCs are in futuristic domain for conducting clinical trials across all the three Germinal Layers.